Liver News and Research

RSS

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

A team led by researchers from the Center for Engineering in Medicine at Massachusetts General Hospital has developed a technique that someday may allow growth of transplantable replacement livers. In their report that will be published in Nature Medicine and is receiving early online release, the investigators describe using the structural tissue of rat livers as scaffolding for the growth of tissue regenerated from liver cells introduced through a novel reseeding process.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Sundise to implement Medidata Rave as its EDC and CDM solution

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Traditional Chinese Medicine company Sundise will implement Medidata Rave as its electronic data capture and clinical data management solution. Selected for its ability to offer a broad global reach with local in-country support, Medidata will work with Sundise to conduct its first U.S. trial for its TCM treatment for liver fibrosis and will play a key role in supporting the company's strategy to launch in the U.S.

11 Jun 2010

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.

11 Jun 2010

Cellular response plays a key role in wound healing

Researchers from the University of Illinois at Chicago have discovered that an unexpected cellular response plays an important role in breaking down and inhibiting the formation of excess scar tissue in wound healing.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

AASLD recommends surveillance in patients with cirrhosis who are at high risk of developing HCC

A study conducted by researchers at the Baylor College of Medicine found that fewer than 20% of patients with hepatocellular carcinoma preceded by cirrhosis were monitored for the development of cancer. Full findings of this study are published in the July issue of Hepatology, a journal of the American Association for the Study of Liver Diseases .

10 Jun 2010

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

A controlled trial conducted by researchers at the E-DA Hospital in Kaohsiung, Taiwan, suggests that a combination of band ligation and nadolol may not be the most effective prophylaxis for first variceal bleeding resulting from cirrhosis. Results of this study appear in the July issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Drinking coffee may help prevent diabetes, report scientists

Scientists are reporting new evidence that drinking coffee may help prevent diabetes and that caffeine may be the ingredient largely responsible for this effect. Their findings, among the first animal studies to demonstrate this apparent link, appear in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

10 Jun 2010

Fero Industries enters into Asset Acquisition Agreement with GVEST

Fero Industries, Inc. is pleased to announce that it has entered into an Asset Acquisition Agreement with GVEST Inc., an Ontario Corporation, for the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

10 Jun 2010

University of Missouri researchers to investigate cadmium's potential for causing endometrial cancer

McDonald's announced a recall recently of 12 million "Shrek"-themed collectible glasses because traces of the toxic metal cadmium were found in them. Cadmium, a silver-white metal, is found in many substances, including certain foods and batteries, and experts believe that it might be a carcinogen. In a new study, University of Missouri researchers will investigate cadmium's potential for causing endometrial cancer.

10 Jun 2010

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.

9 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Simcyp releases Population-based ADME Simulator Version 10.0

Simcyp Limited today announces that it has released the latest version of its flagship simulator, further cementing its position as the industry leader in modelling and simulation of drug-drug interactions (DDIs) in virtual populations.

9 Jun 2010

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

9 Jun 2010

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).

9 Jun 2010

Liver News and Research

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Chiasma successfully completes Phase I clinical study of Octreolin

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

Sundise to implement Medidata Rave as its EDC and CDM solution

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Cellular response plays a key role in wound healing

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

AASLD recommends surveillance in patients with cirrhosis who are at high risk of developing HCC

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

Drinking coffee may help prevent diabetes, report scientists

Fero Industries enters into Asset Acquisition Agreement with GVEST

University of Missouri researchers to investigate cadmium's potential for causing endometrial cancer

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Simcyp releases Population-based ADME Simulator Version 10.0

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News